Skip to main content

Advertisement

Table 4 Saturation grid

From: Integrating the patient voice with clinician reports to identify a hepatocellular carcinoma-specific subset of treatment-related symptomatic adverse events

Sex F M M M M M M M F M M M M M M M M
Age, years 54 62 73 57 66 68 77 84 60 76 65 82 76 64 69 64 72
Treatment-related side effects; n (%)
 Nausea; 6 (35.3%) x    o     o o      o   o  
 Diarrhea; 2 (11.8%) x              o    
 Swelling in legs; 2 (11.8%) x                o  
 Skin breaks/cracks; 1 (5.9%) x                 
 Constipation; 3 (17.6%)    x   o     o         
 Vomiting; 2 (11.8%)     x   o            
 Fatigue/lack of energy/tiredness; 10 (58.8%)     x   o o   o o o o o    o o
 Pain/soreness in/around liver; 3 (17.6%)     x           o   o  
 Pain/tenderness at insertion/injection site; 5 (29.4%)     x   o       o    o o  
 Blisters on feet; 1 (5.9%)     x              
 Soreness around incision; 1 (5.9%)      x             
 Flu-like feeling; 1 (5.9%)       x            
 Lack/loss of appetite/interest in food; 6 (35.3%)       x   o   o   o    o o  
 Hair loss; 4 (23.5%)        x o o         o
 Weakness; 1 (5.9%)        x           
 Increased sweating; 1 (5.9%)         x          
 Uncontrollable urination; 1 (5.9%)         x          
 Urinary urgency; 1 (5.9%)         x          
 Uncontrollable defecation; 1 (5.9%)         x          
 Slept a lot after procedure; 1 (5.9%)         x          
 Itching; 1 (5.9%)         x          
 Memory issues; 2 (11.8%)         x o         
 Weight loss; 1 (5.9%)         x          
 Longer to stop bleeding; 2 (11.8%)          x      o    
 Pain on inside/outside of legs; 1 (5.9%)          x         
 Pain under ribs near right kidney; 1 (5.9%)          x         
 Chills; 1 (5.9%)           x        
 Clogged left ear; 1 (5.9%)           x        
 Nosebleeds; 1 (5.9%)           x        
 Headaches; 2 (11.8%)            x   o     
 Distended abdomen that causes pain; 1 (5.9%)               x    
 Gas (feeling like needing to burp); 1 (5.9%)               x    
 Unpleasant taste in mouth; 1 (5.9%)                x   
  1. Participants are listed sequentially, from left to right, in the order in which interviews were completed
  2. x, first mention by patient; o, subsequent mention by patient